InvestmentJun 26, 2026, 05:21 PM
Akari Therapeutics Consolidates Private Placement Closings
AI Summary
Akari Therapeutics Plc announced an amendment to its previously disclosed securities purchase agreement. The amendment, entered into on June 23, 2026, with certain investors, consolidated the second and third tranches of a private placement into a single closing. This combined closing took place on June 26, 2026, where the company issued and sold the remaining 980,395 American Depository Shares (ADSs) or prefunded warrants. The delivery of associated Series Warrants remains contingent upon shareholder approval at the upcoming annual general meeting on June 30, 2026.
Key Highlights
- Akari Therapeutics previously entered a private placement for 1,470,588 unregistered ADSs.
- The original agreement planned for three tranches, with closings on May 27, June 15, and July 15, 2026.
- An amendment on June 23, 2026, combined the second and third closings into a single event.
- The consolidated closing occurred on June 26, 2026.
- The company issued 980,395 ADSs (or prefunded warrants) at the combined closing.
- Delivery of Series Warrants is contingent on shareholder approval at the June 30, 2026 AGM.
Price Impact
More from AKTX